Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA

Entera Bio Ltd.

2026-Q1 EPS reported $0.07

Net loss of $3.5M ($0.07/share) vs $2.6M in Q1 2025; R&D expenses rose to $2.3M from $1.1M.
Cash $20.4M as of May 8, 2026, including BVF private placement proceeds; runway into Q1 2027.
EB613 Phase 3 protocol submitted to FDA; bridging study completed for single-tablet formulation.
EB612 hypoparathyroidism program prioritized with OPKO; IND expected late 2026.
Geno Germano appointed Chairman in February; Steve Rubin joined Board.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entera Bio Ltd. reported financial results for three months ended March 31, 2026.

Period: three months ended March 31, 2026
Result: reported results

Exact text from the filing

Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-002455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.